All In MedTech

Device type · QXT

Infliximab Test System

FDA groups similar devices under a three-letter product code. This page gathers what FDA's public data says about QXT: how it is classified, what has been cleared or approved, and what has been reported and recalled.

Last checked: Nov 20, 2026Source: openFDAMethods & limitations

How FDA classifies it

Device type
Infliximab Test System
Product code
QXT
Device class
Class II
Review panel
Clinical Toxicology
Regulation
21 CFR 862.3115

Latest FDA decisions

All decisions for QXT

Adverse event reports received per month

By the date FDA received each report, stacked by event type. The newest month is incomplete.

Open in the MAUDE Monitor

No reports to chart for this view.

Manufacturers named most often

Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.

No manufacturers to rank.

Device problems as coded

Last 12 months. FDA's terms. A report can carry several.

No device problems coded.

Patient problems as coded

Last 12 months. FDA's terms. A report can carry several.

No patient problems coded.

Recent recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

No recalls for this product code in FDA's data.

Back to all tools

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.